Consort 2010 statement: extension to cluster randomised trials.

Education and debate CONSORT statement: extension to cluster randomised trials

Reports of cluster randomised trials require additional information to allow readers to interpret them accurately The effective reporting of randomised controlled trials has received useful attention in recent years. Many journals now require that reports conform to the guidelines in the Consolidated Standards of Reporting Trials (CONSORT) statement, first published in 1996 and revised in 2001....

CONSORT statement: extension to cluster randomised trials.

A systematic review of cluster randomised trials in residential facilities for older people suggests how to improve quality.

BACKGROUND Previous reviews of cluster randomised trials have been critical of the quality of the trials reviewed, but none has explored determinants of the quality of these trials in a specific field over an extended period of time. Recent work suggests that correct conduct and reporting of these trials may require more than published guidelines. In this review, our aim was to assess the quali...

Adherence of trials of operative intervention to the CONSORT statement extension for non-pharmacological treatments: a comparative before and after study

INTRODUCTION Use of the Consolidated Standards of Reporting Trials (CONSORT) statement has been shown to improve the reporting of randomised controlled trials and it is endorsed by leading surgical journals. The CONSORT statement for non-pharmacological treatment (CONSORT-NPT) provides specific items to aid in the reporting of trials of operative intervention. This study compares the reporting...

Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.

The CONSORT (Consolidated Standards of Reporting Trials) Statement, which includes a checklist and a flow diagram, is a guideline developed to help authors improve the reporting of the findings from randomized controlled trials. It was updated most recently in 2010. Its primary focus is on individually randomized trials with 2 parallel groups that assess the possible superiority of one treatmen...